1.

Economic analysis of the use of drug-eluting stents in the perspective of the Belgian health care sector

2.

Economic analysis of the use of drug-eluting stents in the perspective of the Belgian health care sector

3.

Economic analysis of the use of drug-eluting stents in the perspective of the Belgian health care sector

4.

Economic analysis of the use of drug-eluting stents in the perspective of the Belgian health care sector

1.

Gender sensitiveness of Belgian aid discourse and practice at the turn of the century

2.

Gender sensitiveness of Belgian aid discourse and practice at the turn of the century

3.

Gender sensitiveness of Belgian aid discourse and practice at the turn of the century

4.

Gender sensitiveness of Belgian aid discourse and practice at the turn of the century

1.

A Missense Variant in KCNJ10 in Belgian Shepherd Dogs Affected by Spongy Degeneration with Cerebellar Ataxia (SDCA1).

2.

A Missense Variant in KCNJ10 in Belgian Shepherd Dogs Affected by Spongy Degeneration with Cerebellar Ataxia (SDCA1).

3.

A Missense Variant in KCNJ10 in Belgian Shepherd Dogs Affected by Spongy Degeneration with Cerebellar Ataxia (SDCA1).

4.

A Missense Variant in KCNJ10 in Belgian Shepherd Dogs Affected by Spongy Degeneration with Cerebellar Ataxia (SDCA1).

1.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

2.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

3.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

4.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

5.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

6.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

7.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

8.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

9.

Gold options, an attractive investment instrument for the non-U.S. investor : the case of the Belgian and Dutch investor

1.

Interlocking directorates and business groups: Belgian evidence

2.

Interlocking directorates and business groups: Belgian evidence

3.

Interlocking directorates and business groups: Belgian evidence

4.

Interlocking directorates and business groups: Belgian evidence

1.

Comparing management performances of Belgian football clubs

2.

Comparing management performances of Belgian football clubs

3.

Comparing management performances of Belgian football clubs

4.

Comparing management performances of Belgian football clubs

1.

High incidence of the CFTR mutations 3272-26A G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A G, E588V, and 1671insTATATCA)

2.

High incidence of the CFTR mutations 3272-26A G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A G, E588V, and 1671insTATATCA)

3.

High incidence of the CFTR mutations 3272-26A G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A G, E588V, and 1671insTATATCA)

4.

High incidence of the CFTR mutations 3272-26A G and L927P in Belgian cystic fibrosis patients, and identification of three new CFTR mutations (186-2A G, E588V, and 1671insTATATCA)

1.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

2.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

3.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

4.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

5.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

6.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

7.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

8.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

9.

Risk communication and human biomonitoring: which practical lessons from the Belgian experience are of use for the EU perspective?

1.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

2.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

3.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

4.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

5.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

6.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

7.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

8.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

9.

Impact of reimbursement restrictions on the choice of antiepileptic drugs: Belgian Study on Epilepsy Treatment (BESET)

1.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

2.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

3.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

4.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

5.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

6.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

7.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

8.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"

9.

Implementation of a program for type 2 diabetes based on the Chronic Care Model in a hospital-centered health care system: "the Belgian experience"